Correlation between insulin resistance surrogates and echocardiographic findings in asymptomatic patients with morbid obesity: A cross-sectional study

Endocrine Practice

Volumn 13, Issue 6, 2007, Pages 590-600

  Ybarra, Juan ^a   Pou, Jose M ^b   Planas, Francesc ^a   Ballesta López, Carlos ^a   Echevarne, Fernando ^c   Romeo, June H ^d   Navarro López, Francisco ^a  

^a CENTRO MÉDICO TEKNON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Laboratori Echevarne   (Spain)

^d Southwest Rheumatology and Research Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD; BODY MASS; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INSULIN RESISTANCE; MALE; METHODOLOGY; MORBID OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; STATISTICAL MODEL;

ADIPONECTIN; ADULT; BODY MASS INDEX; CHOLESTEROL, HDL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INSULIN RESISTANCE; LINEAR MODELS; MALE; OBESITY, MORBID; PROGNOSIS; TRIGLYCERIDES;

EID: 38449115721     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.6.590     Document Type: Article

References (53)

1. Donahue RP, Abbott RD, Bloom E, Reed DM, Yano K. Central obesity and coronary heart disease in men. Lancet. 1987;1:821-824.
2. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
3. Bonora E, Zavaroni I, Bruschi F, et al. Peripheral hyperinsulinemia of simple obesity: pancreatic hypersecretion or impaired insulin metabolism? J Clin Endocrinol Metab. 1984;59:1121-1127.
4. Bloomgarden ZT. Obesity and diabetes. Diabetes Care. 2000;23:1584-1590.
5. Sjöström L. Mortality of severely obese subjects. Am J Clin Nutr. 1992;55(Suppl):516S-523S.
6. Denke MA, Sempos CT, Grundy SM. Excess body weight: an underrecognized contributor to high blood cholesterol levels in white American men. Arch Intern Med. 1993;153:1093-1103.
7. World Health Organization. Obesity: preventing and managing the global epidemic; report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253.
8. Després JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis. 1990;10:497-511.
9. Olefsky J, Reaven GM, Farquhar JW. Effects of weight reduction on obesity: studies of carbohydrate and lipid metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest. 1974;53:64-76.
10. Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven G. Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol. 1985;248(3 Pt 1):E286-E291.
11. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity: European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997;100:1166-1173.
12. Abbasi F, Brown BW, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol. 2002;40:937-943.
13. Reaven G. All obese individuals are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individuals. Diab Vasc Dis Res. 2005;2:105-112.
14. Ingelsson E, Sundström J, Arnlöv J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA. 2005;294:334-341.
15. Aurigemma GP, Gaasch WH. Clinical practice: diastolic heart failure. N Engl J Med. 2004;351:1097-1105.
16. Rakatzi I, Ramrath S, Ledwig D, et al A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes. 2003;52:2227-2238.
17. Evrengul H, Dursunoglu D, Kaftan A, Kilicaslan F, Tanriverdi H, Kilic M. Relation of insulin resistance and left ventricular function and structure in non-diabetic patients with essential hypertension. Acta Cardiol. 2005;60:191-198.
18. Horio T, Suzuki M, Suzuki K, et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens. 2005;18:949-957.
19. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
20. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol. 1976;37:7-11.
21. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation. 1977;55:613-618.
22. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987;59:956-960.
23. Quiñones MA, Mokotoff DM, Nouri S, Winters WL, Miller RR. Noninvasive quantification of left ventricular wall stress: validation of method and application to assessment of chronic pressure overload. Am J Cardiol. 1980;45:782-790.
24. Quiñones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA (Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography). Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002;15:167-184.
25. Alam M, Wardell J, Andersson E, Samad BA, Nordlander R. Characteristics of mitral and tricuspid annular velocities determined by pulsed wave Doppler tissue imaging in healthy subjects. J Am Soc Echocardiogr. 1999;12:618-628.
26. Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler- catheterization study. Circulation. 2000;102:1788-1794.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RL. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412-419.
28. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify over-weight individuals who are insulin resistant. Ann Intern Med. 2003;139:802-809.
29. McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 2005;96:399-404.
30. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
31. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-977.
32. Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D, McMurray JJ. Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15,000 middle-aged men and women (the Renfrew-Paisley Study). Eur Heart J. 2006;27:96-106.
33. Ounpuu S, Negassa A, Yusuf S. INTER-HEART: a global study of risk factors for acute myocardial infarction. Am Heart J. 2001;141:711-721.
34. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305-313.
35. Pascual M, Pascual DA, Soria F, et al. Effects of isolated obesity on systolic and diastolic left ventricular function. Heart. 2003;89:1152-1156.
36. Scaglione R, Dichiara MA, Indovina A, et al. Left ventricular diastolic and systolic function in normotensive obese subjects: influence of degree and duration of obesity. Eur Heart J. 1992;13:738-742.
37. Chakko S. Diastolic dysfunction. In: Alpert MAAJ, ed. Obesity and Ventricular Function in Man. New York, NY: Armonk, 1998: 57-76.
38. Zarich SW, Kowalchuk GJ, McGuire MP, Benotti PN, Mascioli EA, Nesto RW. Left ventricular filling abnormalities in asymptomatic morbid obesity. Am J Cardiol. 1991;68:377-381.
39. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci. 2001;321:225-236.
40. Wong CY, O'Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation. 2004;110:3081-3087.
41. Leichman JG, Aguilar D, King TM, Vlada A, Reyes M, Taegtmeyer H. Association of plasma free fatty acids and left ventricular diastolic function in patients with clinically severe obesity. Am J Clin Nutr. 2006;84:336-341.
42. Di Bello V, Santini F, Di Cori A, et al. Obesity cardiomyopathy: is it a reality? An ultrasonic tissue characterization study. J Am Soc Echocardiogr. 2006;19:1063-1071.
43. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol. 2006;48:1548-1551.
44. Haffner SM, Mykkänen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101: 975-980.
45. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57-63.
46. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes. 2006;55:1537-1545.
47. Ybarra J, Sánchez J, Pou JM, et al. Anthropometrical measures are easily obtainable sensitive and specific predictors of insulin resistance in healthy individuals. Prevention Control. 2005;1:175-181.
48. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003; 144:2195-2200.
49. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270:26746-26749.
50. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473-2476.
51. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003;149:331-335.
52. Vendrell J, Broch M, Vilarrasa N, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004;12:962-971.
53. Owecki M, Miczke A, Pupek-Musialik D, et al. Circulating serum adiponectin concentrations do not differ between obese and non-obese Caucasians and are unrelated to insulin sensitivity. Horm Metab Res. 2007;39:25-30.